The re-emergence of cancer vaccines
Gerold Schuler, MD of University Hospital Erlangen, Erlangen, Germany explains how attitudes have changed towards the use of cancer vaccines in melanoma. Whilst attending the 2016 World Congress on Ca...
Author: VJOncology
Added: 09/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2016 Category: Cancer & Oncology Source Type: podcasts
What's next in melanoma research on drug resistance?
Clemens Krepler, MD of the Wistar Institute, Philadelphia, PA, discusses the developments of the research on mouse models for melanoma. Prof. Kepler explains that the standard of care is increasingly ...
Author: VJOncology
Added: 09/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy news for skin cancer from WCCS/EADO 2016 congress
Beate Lichtenberger, PhD of the Medical University of Vienna, Vienna, Austria, discusses her highlights from the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Asso...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
Why dynamic heterogeneity is important for designing drugs in melanoma
Nikolas Haass, MD, PhD of the University of Queensland, Brisbane, Australia discusses the work of his lab on dynamic heterogeneity in the context of melanoma and his talk given at the World Congress o...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
BRIM-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies
Axel Hauschild, MD, PhD of University Hospital Schleswig-Holstein, Kiel, Germany, discusses the evaluation of long-term survival and prognostic subgroups of overall survival (OS) for the BRIM-3 trial ...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
Treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
Marius Erik Mayerhfer, MD, PhD of the Medical University of Vienna, Vienna, Austria gives an overview of his talk on treatment response assessment in melanoma held at the World Congress on Cancers of...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
The Anti-Melanoma Tent health initative
Petr Arenberger, MD, PhD, DSc, MBA of Charles University, Prague, Czech Republic discusses the Anti-Melanoma Tent initative, where experts travel to big cities in the Czech Rebuplic and examine patien...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
Why uveal melanoma is a good candidate for vaccination and the importance of the abnormal ligandome
Gerold Schuler, MD of University Hospital Erlangen, Erlangen, Germany discusses cancer vaccines and in particular, the potential to develop a vaccine for uveal melanoma at the 2016 World Congress on C...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
Melanoma patients who discontinued nivolumab plus ipilimumab treatment experienced equal or better PFS
Dirk Schadendorf, MD of University Hospital Essen, Essen, Germany discusses the results of the efficacy and quality of life outcomes in patients with advanced melanoma who discontinued nivolumab plus ...
Author: VJOncology
Added: 09/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - September 12, 2016 Category: Cancer & Oncology Source Type: podcasts
